Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 04, 2020 08:00 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb

CAMBRIDGE, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
March 06, 2019 06:30 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

- New data from two programs to be presented at AACR - - New Phase 2 studies to be initiated in 2019 supported by established safety from dose escalation cohorts of vopratelimab (JTX-2011), with...